ロード中...
The potent and selective α4β2*/α6*-nicotinic acetylcholine receptor partial agonist 2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol demonstrates antidepressive-like behavior in animal models and a favorable ADME-tox profile
Preclinical and clinical studies demonstrated that the inhibition of cholinergic supersensitivity through nicotinic antagonists and partial agonists can be used successfully to treat depressed patients, especially those who are poor responders to selective serotonin reuptake inhibitors (SSRIs). In o...
保存先:
主要な著者: | , , , , , , , , , , , , , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
BlackWell Publishing Ltd
2014
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4184702/ https://ncbi.nlm.nih.gov/pubmed/25505580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.26 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|